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Dysfunction of biological stress systems and adverse life events, both independently and in interaction, have been hypothesized to predict chronic pain persistence. Conversely, these factors may hamper the improvement of chronic pain. Longitudinal evidence is currently lacking. We examined whether (1) function of biological stress systems, (2) adverse life events, and (3) their combination predict the improvement of chronic multi-site musculoskeletal pain. Subjects of the Netherlands Study of Depression and Anxiety (NESDA) with chronic multi-site musculoskeletal pain at baseline (n=665) were followed-up 2, 4 and 6 years later. The Chronic pain Grade Questionnaire was used to determine improvement (not meeting the criteria) of chronic multi-site musculoskeletal pain at follow-up. Baseline assessment of biological stress systems included function of hypothalamic-pituitary-adrenal axis (1-h cortisol awakening response, evening level and post-dexamethasone level), the immune system (basal and lipopolysaccharide-stimulated inflammatory markers), the autonomic nervous system (heart rate, pre-ejection period, SD of the normal-to-normal interval, respiratory sinus arrhythmia). The number of adverse life events were assessed at baseline and 2-year follow-up using the List of Threatening Events Questionnaire. We showed that hypothalamic-pituitary-adrenal axis, immune system and autonomic nervous system functioning and adverse life events were not associated with the improvement of chronic multi-site musculoskeletal pain, either as a main effect or in interaction. This longitudinal study could not confirm that biological stress systems dysfunction and adverse life events affect the course of chronic multi-site musculoskeletal pain. 

Perspective 
Biological stress systems and adverse life events are not associated with the improvement of chronic multi-site musculoskeletal pain over 6 years follow-up. Other determinants should thus be considered in future research to identify in which persons pain symptoms will improve.
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Chronic pain is a common and persistent problem in the community[16]. However, some persons show improvement in pain symptoms[13] and it is useful to examine which factors identify these persons. Both biological and psychosocial stress factors may play a role in the deterioration, persistence or the improvement of chronic pain[13].  
Considering biological factors, subjects with chronic pain have previously shown alterations in biological stress systems[1,23]. Previous cross-sectional studies indicate that dysfunction of the hypothalamic-pituitary-adrenal axis (HPA-axis), the immune system (IMS) and the autonomic nervous system (ANS) promote neural alterations that have been associated with central sensitization processes in pain disorders[33]. Furthermore, psychosocial trigger incidents, such as adverse life events, may among others exacerbate chronic pain through their effect on biological stress systems[33,36]. Support for this model (see Figure 1) comes mainly from cross-sectional findings hence causal directions remain uncertain. 
To be more precise, previous cross-sectional studies showed lower levels of HPA-axis cortisol[18,34,44] and increased sensitivity to feedback inhibition of the HPA-axis[50] in chronic pain. In other studies, individuals with chronic pain showed an increased innate immune response[20,26] and altered parasympathetic and sympathetic activity of the autonomic nervous system[12,41]. Longitudinal studies examining the role of biological stress systems in chronic pain are scarce and mainly focused on the onset of chronic pain[36]. One prospective study found that altered function of the HPA-axis predicted the onset of chronic widespread pain[36]. Thus, although function of biological stress systems might be altered in chronic pain, its association with the persistence or improvement of chronic pain remains unclear. 
With regard to psychosocial stress factors, cross-sectional studies suggest an association between recent adverse life events and chronic pain[3,27]. Longitudinal studies showed that adverse life events were associated with the future onset of chronic pain[24,25]. One prospective study found that experiencing two or more negative events (related to relationships, unemployment, illness or financial problems) predicted new-onset chronic widespread pain 15 months later[24]. Nevertheless, the role of life events in relation to the future course of chronic pain remains to be elucidated.  
Most previous studies examining biological stress systems and life events in relation to chronic pain did not take relevant confounders into account, even though previous work has indicated that lifestyle[13,37,47], chronic diseases[13,37] and psychopathology[21,47] may influence both biological stress systems and chronic pain. For example, older age and chronic diseases (such as cardiovascular disease) have been associated with increased cortisol levels[48], and an increased risk of persisting chronic pain[32,37]. In addition, previous research has shown that psychopathology[18] and pain status at baseline[16] might not only confound, but also moderate the association between biological function and chronic pain. We showed in a previous study that hypocortisolemia was only present in subjects with chronic pain without depressive and anxiety disorders, as these disorders seem to conversely increase cortisol levels[18]. To test this, interaction of biological variables with psychopathology have to be examined in the association between biological stress systems and chronic pain. There is a lack of large-scale longitudinal studies that take these relevant confounders and moderators into account.
This 6-year longitudinal study followed 665 subjects who had chronic multi-site musculoskeletal pain at baseline to determine the association of baseline (1) dysfunction of the HPA-axis, IMS and ANS, (2) adverse life events, and (3) the interaction of biological dysfunction and life events, with the improvement of chronic multi-site musculoskeletal pain across a six-year follow-up, while adjusting for sociodemographics, lifestyle, chronic diseases, depression, and anxiety. We hypothesize that biological stress systems and life events both contribute to the maintenance of chronic pain.

Methods
Study design, data collection procedures, and study sample
The present study used longitudinal data from the Netherlands Study of Depression and Anxiety (NESDA): an ongoing cohort study in which 2981 participants (18-65 years at baseline), from which 94.8% were of North-European ancestry, were monitored biannually for 6 years to investigate the long-term course and consequences of depressive and anxiety disorders. Participants were recruited from the community (19%), primary care (54%), and specialized mental health care (27%). The community sample builds on two Dutch cohorts that were available through prior studies[8,28]. Primary care patients were recruited from 65 general practitioners through a three-stage screening procedure including screening questionnaires and phone interviews. People in different developmental stages of psychopathology as well as controls with no psychiatric diagnosis participated. The disorders included dysthymia, major depressive disorder, general anxiety disorder, panic disorder, social phobia, and agoraphobia. Due to the design of the NESDA study, exclusion criteria were not being fluent in Dutch or a diagnoses of a primary psychiatric diagnosis other than depression and anxiety (e.g. psychotic disorder, obsessive compulsive disorder, or severe addiction disorder as assessed by DSM criteria using the Composite International Diagnostic Interview[42]). Baseline data collection took place between 2004 and 2007, with follow-up assessments 2, 4 and 6 years later. Data collection was performed by specially trained clinical research staff at the three research sites in the Netherlands (Amsterdam, Groningen and Leiden) and included assessment of written questionnaires, interviews, a medical examination and collection of blood and saliva samples. The NESDA study contains a high proportion of subjects with chronic multi-site musculoskeletal pain and provides a unique opportunity to control for relevant variables such as depressive and anxiety disorders. The research protocol was approved by the Ethical Committee of participating universities and written informed consent was obtained from all participants. Penninx et al.[39] provided a detailed description of the NESDA study design and sampling procedures.
Participants with chronic multi-site musculoskeletal pain at baseline were included in the present study (n=767) and followed up for the improvement of chronic multi-site musculoskeletal pain over 6 years. Of these eligible subjects, 665 subjects had data on pain at follow-up (2, 4 or 6 year) available (therefore, n=102 were lost to follow-up). Baseline data were assessed on biological stress systems function and adverse life events. All subjects had baseline data available for adverse life events or for at least one marker of the biological stress systems. 

Improvement of chronic multi-site musculoskeletal pain
Chronic multi-site musculoskeletal pain was defined using the Chronic Pain Grade (CPG; [46]). The CPG first inquires about the presence of pain in the prior six months in the extremities (joints of the arms, hands, legs or feet), back, neck, head, abdomen, chest, and the orofacial area (mouth and face)[45]. The subsequent questions in the CPG refer to the most painful location and inquire 1) days in pain in the prior six months (scale 0-180); 2) pain at this moment (scale 0-10); 3) worst pain in the prior six months (scale 0-10); 4) average pain in the prior six months (scale 0-10); 5) disability days in the prior six months (scale 0-180); 6) disability in daily activities (scale 0-10); 7) disability in spare time, social life, and family activities (scale 0-10); and 8) disability in work (scale 0-10). For the assessment of pain severity, a total pain intensity score was calculated using questions 2, 3 and 4 of the CPG, and a total pain disability score was calculated using questions 6, 7 and 8 of the CPG [average of the 0-10 ratings of the 3 questions multiplied by 10 resulting in a 0-100 score]. Disability points (scale 0-6) were calculated adding the total disability score (0-100) and the indicated points for disability days (question 5 of the CPG) (see [46] and supplementary Table 1). Five grades were categorized: grade 0 (pain free, no pain in the prior six months); grade I (low disability [less than 3 disability points], low intensity [score below 50]); grade II (low disability, high intensity [score 50 or higher]); grade III (high disability, moderately limiting [3-4 disability points regardless of pain intensity score]); and grade IV (high disability, severely limiting [5-6 disability points regardless of pain intensity score]) (see [46] and supplementary Table 2). Following our previous studies[18,20], we defined chronic multi-site musculoskeletal as grade I, II, III or IV on the CPG and pain present in the prior six months in the extremities, the back and the neck. Improvement was defined as being free of chronic multi-site musculoskeletal pain (in the prior 6 months) at one of the follow-up time points (2, 4 or 6 years). Time to improvement described the first time-point at which improvement occurred. Subjects whose chronic multi-site musculoskeletal pain did not improve were classified as ‘persistent’ and still met the criteria of chronic multi-site musculoskeletal pain at all follow-up time points. All subjects were censored in the analysis at the occurrence of improvement or at the last recorded follow-up. 
 
Biological stress systems
Function of the HPA-axis was assessed by collection of saliva samples at home using Salivettes (Sarstedt AG and Co, Numbrecht, Germany) at seven time points within a median of 9 days (IQR=5-22) after the baseline interview. Cortisol analysis was performed by competitive electrochemiluminescence (E170 Roche, Switzerland). The cortisol awakening response included sampling points at awakening, and 30, 45, and 60 minutes later. Using formulas described by Pruessner et al.[40], the area under the curve with respect to the ground (AUCg) and with respect to the increase (AUCi) were calculated based on the four morning cortisol measures[48]. The AUCg is an estimate of the total cortisol secretion over the first hour of awakening, whereas the AUCi is a measure of the dynamic of the cortisol awakening response related to the sensitivity of the system and emphasizing the rate of change of the cortisol levels after awakening. In line with our previous work[47], we only used AUCg and AUCi as markers of the cortisol awakening curve in our analyses. Evening cortisol was averaged over two evening values (10 p.m. and 11 p.m.). To provide a measure of the negative feedback system of the HPA-axis, the cortisol suppression ratio was calculated as the cortisol value at awakening on the first day divided by the cortisol value at awakening on the next day after ingestion of 0.5mg dexamethasone the evening before (directly after the saliva sample at 11 p.m.). Cortisol values were assigned as missing if samples were collected outside of a margin of five minutes before or after the time protocol. Also, a pilot test has been performed to rule out non-compliance with dexamathosone ingestion [see [47,48] for details on cortisol assessment and data cleaning procedures].
For function of the IMS, both basal inflammation and the innate immune response were assessed as they have previously been related to chronic pain[20]. Fasting morning blood samples were kept frozen at -80°C and basal levels of inflammatory markers C-reactive protein (CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α were assayed. CRP was assayed using a high-sensitivity in-house ELISA based on purified protein and polyclonal anti-CRP antibodies (Dako, Glostrup, Denmark). IL-6 was assayed using a high-sensitivity ELISA (PeliKine-CompactTM ELISA, Sanquin, Amsterdam, The Netherlands). TNF-α was assayed using a high-sensitivity solid-phase ELISA (Quantikine HS Human TNF-α Immunoassay, R&D systems Inc, Minneapolis, MN, USA). Following our previous studies[19,20], a basal summary index was calculated as the standardized sum of all three standardized ln-transformed basal inflammatory markers. The innate immune response of 13 cytokines was determined in whole blood that was ex vivo stimulated with lipopolysaccharide (LPS; 10 ng/ml blood). LPS-stimulated samples were laid flat and incubated at a slow rotation for 5–6 hours at 37°C. Plasma was kept frozen at -80°C. Using a multi-analyte profile (Human CytokineMAP A v 1.0; Myriad RBM, Austin, TX, USA), interferon-γ, IL-2, IL-4, IL-6, IL-8, IL-10, IL-18, C-C motif chemokine 2 (CCL2), CCL3, CCL4, matrix metalloproteinase-2, TNF-α and TNF ligand superfamily member 1 were determined. As all cytokines were highly intercorrelated (Pearson’s r: mean±SD=0.60±0.18), an LPS summary index was calculated as the standardized sum of all 13 standardized ln-transformed markers. To avoid multiple testing, only the basal summary index and LPS summary index were used in the analyses.
ANS assessment was performed using the VU University Ambulatory Monitoring System (VU-AMS) device, recording the electrocardiogram and changes in thorax impedance from six electrodes placed on the chest and back for a period of ~2 hours[14,49]. ANS markers included heart rate and pre-ejection period (PEP) as markers of sympathetic activity; and SD of the normal-to-normal interval (SDNN) and respiratory sinus arrhythmia (RSA) as markers of parasympathetic activity of the ANS [see [5,31] for details]. 

Adverse life events





Baseline covariates were selected a priori based on previous findings of important determinants of biological stress systems function and chronic pain. A first set of covariates included sociodemographic characteristics (age, sex, and years of education) and sampling factors. Older age[16,32], female sex and less education[32] have been associated with persistence of chronic pain. For HPA-axis analyses, cortisol sampling factors were considered including awakening time, working on day of sampling (yes/no), season (light vs. dark month), and <6h sleep (yes/no) as they have previously been found to determine HPA-axis cortisol levels[48]. For the LPS summary index analyses, laboratory site (Amsterdam, Groningen, Leiden, Heerenveen) was considered to account for potentially small differences in the assessment of LPS-stimulated inflammatory levels across sites. For RSA analyses, respiration rate (breaths/minute) was considered as a covariate as it influences respiratory sinus arrhythmia and vagal tone[22]. A second set of covariates comprised several lifestyle and disease factors, which were selected based on previous associations with either biological stress systems[13,47] or pain[37]. Higher body mass index[37], alcohol consumption[6], former smoking[37], lower physical fitness[17] and chronic diseases[37] were previously associated with chronic pain. Body mass index was calculated as body weight in kilograms divided by height in meters squared. Smoking was categorized as never, former or current smoker. Alcohol intake was categorized as non-drinker, mild/moderate drinker or heavy drinker[53]. Physical activity was assessed with the International Physical Activity Questionnaire and expressed as one’s resting metabolic rate multiplied by minutes of physical activity per week (MET-minutes per week)[2]. Total number of chronic diseases (including cardiovascular disease, epilepsy, diabetes mellitus, osteoarthritis, stroke, cancer, chronic lung disease, thyroid disease, liver disease, intestinal disorders, and ulcers) were assessed by self-report. Medication use was based on drug container inspection of all drugs used in the past month and classified according to the World Health Organization Anatomical Therapeutic Chemical (ATC) classification[52]. In line with our previous work[5,19], we considered frequent use (daily or >50% of the time) of medication that affects either biological stress systems or pain[15,52]. For IMS analyses, anti-inflammatory medication (ATC codes: M01A, M01B, A07EB, A07EC) was considered. For ANS analyses, heart medication (β-blocking agents [ATC code: C07] and other heart medication [ATC codes: C01, C02, C03, C04, C05, C08, C09]) were considered. A third set of covariates included lifetime (current and prior) diagnoses of depressive and/or anxiety disorders and use of antidepressant medication. Depression and anxiety have previously been associated with altered sympathetic and parasympathetic balance, HPA-axis dysregulation and altered immune function[33]. Pain increases the onset of these disorders[21]. In addition, depression and anxiety might moderate the association between biological stress systems, such as the HPA-axis, and chronic pain[18]. Use of antidepressants might supress depression, anxiety and pain[33]. Lifetime diagnoses of depressive disorders (major depressive disorder, dysthymia) and anxiety disorders (panic disorder, agoraphobia, generalized anxiety disorder, social phobia) were established with the Composite International Diagnostic Interview (WHO version 2.1) according to DSM-IV criteria[42]. Use of tricyclic antidepressants (ATC code: N06AA), selective serotonin reuptake inhibitors (ATC code: N06AB) and other antidepressant medications (ATC codes: N06AF/AG/AX) was assessed. 

Statistical analyses 
Baseline characteristics were compared between subjects with and without improvement of chronic multi-site musculoskeletal pain using independent-samples t-tests for continuous variables, χ2 tests for dichotomous and categorical variables, and Mann-Whitney U tests for non-normally distributed variables. Cox’s regression analyses were performed to determine the associations between biological stress systems and adverse life events at baseline and improvement of chronic multi-site musculoskeletal pain over 6 years follow-up, while adjusting for confounders in three steps: (1) sociodemographic variables (age, sex and years of education), cortisol sampling factors (in HPA-axis analyses), laboratory site (in LPS analyses), and respiration rate (breaths/minute, in RSA analyses); (2) ‘lifestyle and disease’: body mass index, smoking, alcohol intake, physical activity, chronic diseases, anti-inflammatory medication (IMS analyses) and β-blocking agents and heart medication (ANS analyses), (3) lifetime depression and/or anxiety and antidepressant use. Unique aspects of the Cox’s approach are studying time at risk for an event and the censoring of data at the last recorded follow-up measure if subsequent data are missing or if no event occurs. Proportional hazards were verified. Values for evening cortisol, cortisol suppression ratio and basal inflammatory markers were ln-transformed prior to analyses to normalize distributions. Missing data of biological stress systems were at random (Little Missing Completely At Random (MCAR) test: p=.45). Life events at 2-year follow-up were used for sensitivity analyses to test whether they were further predictive of improvements in chronic multi-site musculoskeletal pain at later follow-up measures. 
 A potential moderating effect of life events in the association between function of biological stress systems and improvement of chronic multi-site musculoskeletal pain was examined by adding an interaction term (biological marker*number of life events) to each analysis. Also, since psychopathology[18] and pain intensity at baseline[16] might moderate the association between biological function and chronic multi-site musculoskeletal pain, interaction terms ([biological marker*lifetime depression and/or anxiety]; [biological marker*pain intensity at baseline]) were separately tested and added to the analyses. 
For all statistical tests, a probability level of ≤5% was regarded as significant. To test interactions, this level was set at ≤10%. The statistical calculations were performed using SPSS 20 for Windows (IBM, Armonk, NY, USA).

Results
Included subjects (n=665) had lower baseline values for cortisol suppression ratio (median[IQR]=2.3[1.7-3.0] vs. 2.9[2.1-3.6], p=.02), C-reactive protein (median[IQR]=1.3[0.6-2.9] vs. 1.5[0.9-4.7], p=.05), respiratory sinus arrhythmia (mean[SD]=40.5[21.4] vs. 48.0[33.1], p=.003) and higher total number of adverse life events (mean[SD]= 1.0[1.4], 0.7[1.0], p=.02), but did not differ from excluded subjects who were lost to follow-up (n=102) in the other variables of biological stress systems (p>.05).
Of 665 subjects with chronic multi-site musculoskeletal pain at baseline, 28% (n=185) still met the criteria for chronic multi-site musculoskeletal pain at all available follow-up time points. Of the subjects who improved (n=480, 72%), average time to improvement was 3 years (46% improved after 2 years, an additional 17% after 4 years, and an additional 9% after 6 years). Subjects with improvements in chronic multi-site musculoskeletal pain had lower baseline pain scores, were significantly younger, had more years of education, worked more often on day of cortisol sampling, and sleep more than subjects with persistence of chronic multi-site musculoskeletal pain. Moreover, the group with pain improvement had lower body mass index, were more often moderate alcohol drinkers, were more often physically active, had less often chronic diseases, used less often other heart medication, had less often a lifetime depressive or anxiety disorder, had lower values of IL-6, and higher values of SDNN and RSA than the persistent group (see Table 1).	
Table 2 shows associations between function of the biological stress systems and improvement of chronic multi-site musculoskeletal pain. None of the HPA axis, IMS and ANS variables were associated with improvement of chronic multi-site musculoskeletal pain after adjustment for covariates (all p>0.05). Table 3 reports the association between the total number of adverse life events and improvement of chronic multi-site musculoskeletal pain. Similar to the unadjusted model, no significant associations were found for any of the predictors after adjusting for sociodemographic or more extensive sets of covariates (all p>.05). 
Additional analyses showed that the number of life events assessed at 2-year follow-up were not further predictive of improvement of chronic multi-site musculoskeletal pain at later follow-up measures (n=628; fully adjusted HR[95%CI]=0.96[0.90-1.02], p=.18). Also, no moderating effects of life events in the association between any of the markers of the biological stress systems and improvement of chronic multi-site pain were found (all p-interaction > .10). Moreover, no evidence was found for moderating effects of psychopathology and pain intensity at baseline in the association between biological stress systems and improvement of chronic multi-site musculoskeletal pain (all p-interaction > .10). Additional analyses examining a short follow-up period restricted to 2 years also showed no associations between biological stress systems and life events with improvement of chronic multi-site musculoskeletal pain (n=628; similar hazard ratios and all p>.30). In order to test whether our findings were not influenced by chronic pain severity at baseline, we performed analyses while adjusting for all covariates including baseline pain intensity scores and also found similar non-significant hazard ratios for each predicting variable (all p>.10). Similarly, adjusting for pain disability or number of pain days at baseline did not affect our findings. Following a previous study[13], we additionally tested whether pain severity at follow-up affected our findings. However, the inclusion of pain intensity or pain disability at 2-year follow-up separately as confounders in our fully adjusted analyses showed similar hazard ratios (analyses restricted to 2 year follow-up, n=628; all p>.40). Approximately 12% of our sample regularly used benzodiazepines (ATC codes: N03Ae, N05BA, N05CD, N05CF). We therefore performed additional analyses adding this as a confounder to our model. This did not affect our findings: similar non-significant hazard ratios were found for both biological variables and life events with chronic pain improvement.
	
Discussion 
This longitudinal study showed that improvement of chronic multi-site musculoskeletal pain was neither predicted by HPA-axis, IMS and ANS functioning, nor by adverse life events or the interaction between biological stress system function and life events. Therefore, our study does not confirm the hypothesis that biological or psychosocial stress contribute to the maintenance of chronic pain[33]. 
Previous cross-sectional studies, including NESDA studies, did indicate modest associations between biological stress systems and chronic multi-site musculoskeletal pain[18,20,34]. However, our previous prospective NESDA study did also show no associations between biological stress systems and the onset of chronic multi-site musculoskeletal pain[19]. Because concurrent but no prospective associations are found between biological stress systems and the onset or persistence of chronic pain, it appears that biological alterations do not precede chronic pain. Instead, biological alterations might be a consequence of chronic pain, e.g. by pain acting as a chronic stressor, or as a result of associated symptoms of chronic pain such as fatigue, sleep disturbance, depressed mood, and lower physical activity levels[17]. Another explanation is that a third factor, such as a genetic factor, induces both pain and biological changes.
This study indicated that also adverse life events did not predict the course of chronic multi-site musculoskeletal pain over 6 years. Perhaps life events play a role in the etiology rather than the persistence of chronic pain. In agreement with this, our previous study showed that adverse life events, but not biological stress systems, were associated with a higher risk of developing chronic multi-site musculoskeletal pain over 6 years[19]. From a transactional point of view, life events alone will not affect persistence of chronic multi-site musculoskeletal pain but rather life events in interaction with psychosocial factors such as stress and distress reactions[35] that are also determined by resilience factors. Moreover, attitudes and concerns about illness and health[35], avoidance behavior and catastrophizing cognitions[30] may have an impact on persistence of chronic pain. These factors were not examined in our study.
Some other determinants were indicated to be of importance for improvement of chronic pain. Our finding that older age and a higher number of chronic diseases were associated with persistence of chronic pain concurs with previous research[16,37]. Other relevant determinants of persisting chronic pain might be sociodemographic variables such as female sex and less education, as indicated by previous research[32]. Also, health characteristics such as obesity[37], physical fitness[17] and additional physical or psychological symptoms[32] have shown to influence the course of chronic pain. Whereas poor sleep[37] and high levels of fatigue[32] were previously found to predict persisting chronic pain, restorative sleep was found to predict the resolution of chronic pain in another study[13]. Moreover, high psychological distress and illness behavior such as medical care-seeking behavior has been shown to predict chronic pain persistence[35]. It is possible that our findings for biological stress systems were masked by other variables not assessed in our study, e.g. by associated symptoms of pain such as fatigue or by genetic variables. Nevertheless, this longitudinal study controlled for the effects of a multitude of relevant sociodemographic, pain-related, health-related and psychopathological variables.
The number of subjects with improved chronic multi-site musculoskeletal pain in our study [46% within 2 years, 63% within 4 years, and 72% within 6 years] appears relatively low compared to other previous studies [44% within 1 year[35]; 65% within 2 years[32]]. This lower rate of improvement may be explained by differences in measurement of pain or by a rather high rate of psychological distress[35] in our study due to the design of the Netherlands Study of Depression and Anxiety. Nevertheless, we tested whether psychopathology influenced our findings, both as a potential confounder and moderator, and this was not the case.
There are several methodological considerations to our study related to the assessment of biological variables and pain. First, we assessed biological variables in 1 day, whereas HPA axis, ANS and IMS functioning fluctuates from day-to-day. Second, data were partially missing for LPS-stimulated inflammation and for HPA axis markers. Persons with missing data on LPS-stimulated inflammation did not differ in basal inflammatory levels and chronic pain from those with LPS data[20]. However, missing data may be slightly differential for HPA axis markers because our subjects collected salivary samples at home[18]. A pilot test has been performed to rule out non-compliance with dexamathosone ingestion [see [47,48]. Also, additional missing value analyses showed that all biological data in our sample were indicated to be missing at random. Third, our study did not assess biological function at follow-up. Future studies could elucidate whether changes in biological function over time rather than baseline function determine improvements in chronic pain. Fourth, pain may fluctuate and we assessed pain in the 6 months prior to the follow-up visits, suggesting that some persons might have been misclassified. Fifth, our study did not measure type of pain, and therefore cannot entirely exclude that some of our findings may not hold for specific types of pain. For example, distinct brain alterations have previously been found for neuropathic pain, as compared to inflammatory pain conditions[4,38]. Final considerations concerns the selection of our primary outcome. We examined improvement of chronic multi-site musculoskeletal pain in this study to best profit from the survival data and the large sample size. We were able to study time at risk for an event (i.e. improvement) and to censor data at the last recorded follow-up measure if subsequent data were missing or if no event occurred. Also, the Cox’s regression approach allows to include multiple follow-up time points rather than one follow-up time point, as was done in previous studies[13,37]. Our approach may thus decrease the chance of misclassification of subjects. Nevertheless, reduction of symptoms rather than passing a cutoff criterion may yield somewhat different results. Our classification of chronic multi-site musculoskeletal pain was pain in the extremities, the back and the neck, while most previous studies assessed chronic widespread pain (pain in all four body quadrants)[51]. However, setting broader parameters in studying mechanisms underlying chronic pain might be useful as multi-site musculoskeletal pain without meeting the widespread criteria is also associated with severe disability, high pain intensity and significant psychological distress[11]. Nonetheless, this study has many strong aspects such as the longitudinal design, the large sample size, and the assessment of a wide range of biological markers in relation to chronic pain improvements while adjusting for a large number of covariates. Thus, if dysfunction of biological stress systems would play an important role in the persistence of chronic pain, we should have been able to show this, especially since our cross-sectional findings did indicate biological alterations in chronic multi-site musculoskeletal pain[18,20]. 
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	Persistence of chronic multi-site pain (n=185)	Improvement of chronicmulti-site pain (n=480)	P†
			
Pain scores			
  Pain days	134.8 (61.4)	100.0 (70.2)	<0.001
  Pain intensity	58.3 (15.6)	50.6 (18.0)	<0.001
  Pain disability	48.3 (23.1)	35.9 (26.0)	<0.001
Sociodemographic factors			
  Age, years	48.4 (10.6)	43.8 (12.2)	<0.001
  Women, %	78.4	71.2	0.06
  Education, years	10.8 (3.2)	11.6 (3.2)	0.002
Cortisol sampling factors			
  Time of awakening	7:30 (1:00)	7:30 (0:58)	0.66
  Working on day of sampling, %	57.8	68.5	0.009
  Sampling in month with more daylight, %	68.1	70.8	0.49
  ≤6h sleep, %	43.8	31.0	0.003
Lifestyle and disease factors			
  Body mass index, kg/m2, median [IQR]	26.0 [23.3-29.4]	24.9 [22.4-29.0]	0.03
  Smoking, %			0.31
  Never smoker	27.0	26.5	
  Former smoker	36.2	30.8	
  Current smoker	36.8	42.7	
  Alcohol use, %			0.001
  Non-drinker	48.6	35.4	
  Mild/moderate alcohol drinker 	38.4	54.0	
  Heavy alcohol drinker	13.0	10.6	
  Physical activity, 1000 MET min/week, median [IQR]  	3.3 [1.9-5.0]	3.7 [1.5-5.7]	0.02
  Number of chronic diseases      	1.4 (1.2)	0.9 (0.9)	<0.001
  Anti-inflammatory medication, %	29.7	25.6	0.28
  β-blocking agents, %	12.4	8.8	0.15
  Other heart medication, %	20.0	13.3	0.03
Depression and anxiety factors			
  Lifetime depressive or anxiety disorder, %	92.4	86.7	0.04
  Antidepressant medication, %	30.8	30.4	0.92
Biological stress systems function			
HPA-axis			
  AUCg, nmol/l/h	18.9 (6.9)	18.6 (6.5)	0.70
  AUCi, nmol/l/h	2.8 (6.4)	2.5 (6.1)	0.69
  Mean evening level, nmol/l, median [IQR]	5.4 [3.4-6.9]	4.7 [3.3-6.6]	0.25
  Cortisol suppression ratio, median [IQR]	2.2 [1.7-2.9]	2.4 [1.7-3.1]	0.39

IMS			
  Basal CRP, mg/L, median [IQR]	1.4 [0.68-3.5]	1.3 [0.57-2.8]	0.29
  Basal IL-6, pg/mL, median [IQR]	0.95 [0.60-1.5]	0.78 [0.51-1.2]	0.03
  Basal TNF-α, pg/mL, median [IQR]	0.80 [0.60-1.10]	0.80 [0.60-1.0]	0.14
  Basal summary index	0.11 (0.98)	-0.04 (1.0)	0.10
  LPS summary index	0.15 (0.74)	-0.06 (1.1)	0.11
ANS			
  Heart rate, beats/min	71.6 (9.7)	71.9 (9.2)	0.73
  PEP, msec	120.6 (20.0)	120.8 (17.5)	0.89
  SDNN, msec	60.5 (22.4)	66.7 (24.3)	0.003
  RSA, msec	37.3 (19.4)	41.7 (22.0)	0.02
  Respiration rate, breaths/minute  	17.0 (1.2)	17.0 (1.1)	0.81
Adverse life events			
Total number of adverse life events	0.69 (0.96)	0.77 (1.06)	0.37
* Values are mean ± SD unless otherwise indicated. † Based on independent-samples t-tests for continuous variables, χ2 tests for dichotomous and categorical variables and Mann-Whitney U tests for non-normally distributed variables. 
ANS, autonomic nervous system; AUCg, area under the curve with respect to the ground; AUCi, area under the curve 
with respect to the increase; CRP, C-reactive protein; HPA-axis, hypothalamic-pituitary-adrenal axis; IL-6, interleukin-6; IMS, immune system; LPS, lipopolysaccharide; MET, resting metabolic rate multiplied by minutes of physical activity per week; PEP, pre-ejection period; RSA, respiratory sinus arrhythmia; SDNN, SD of the normal-to-normal interval; TNF-α, tumor necrosis factor-alpha.





Table 2. Associations* between biological stress systems function at baseline and 
improvement of chronic multi-site musculoskeletal pain over 6 years follow-up
		Improvement of chronic multi-site pain	
	N	HR per 1 SD (95%CI)	P
HPA-axis				
  AUCg a  	403			
    Sociodemographic adjusted 1		0.99 (0.88-1.11)		0.82
    Lifestyle & disease adjusted 2		1.00 (0.88-1.13)		0.99
    Depression & anxiety adjusted 3		1.01 (0.89-1.14)		0.90
  AUCi a  	403			
    Sociodemographic adjusted 1		1.00 (0.89-1.12)		0.96
    Lifestyle & disease adjusted 2		1.01 (0.89-1.14)		0.89
    Depression & anxiety adjusted 3		1.01 (0.90-1.14)		0.85
  Mean evening level  a  	439			
    Sociodemographic adjusted 1		0.99 (0.89-1.11)		0.91
    Lifestyle & disease adjusted 2		1.01 (0.89-1.14)		0.91
    Depression & anxiety adjusted 3		1.01 (0.89-1.15)		0.87
  Cortisol suppression ratio a   	415			
    Sociodemographic adjusted 1		1.00 (0.89-1.13)		0.97
    Lifestyle & disease adjusted 2		0.99 (0.89-1.12)		0.92
    Depression & anxiety adjusted 3		1.00 (0.89-1.12)		0.97
IMS				
  CRP b	650			
    Sociodemographic adjusted 1		0.99 (0.90-1.08)		0.80
    Lifestyle & disease adjusted 2		0.99 (0.89-1.10)		0.87
    Depression & anxiety adjusted 3		0.99 (0.89-1.10)		0.99
  IL-6 b	649			
    Sociodemographic adjusted 1		0.99 (0.90-1.09)		0.84
    Lifestyle & disease adjusted 2		1.00 (0.91-1.10)		0.99
    Depression & anxiety adjusted 3		1.00 (0.91-1.10)		0.96
  TNF-α b	647			
    Sociodemographic adjusted 1		0.98 (0.89-1.07)		0.61
    Lifestyle & disease adjusted 2		0.98 (0.89-1.08)		0.69
    Depression & anxiety adjusted 3		0.98 (0.89-1.08)		0.69
  Basal summary index b	643			
    Sociodemographic adjusted 1		0.97 (0.89-1.07)		0.57
    Lifestyle & disease adjusted 2		0.98 (0.88-1.09)		0.71
    Depression & anxiety adjusted 3		0.98 (0.89-1.09)		0.73
  LPS summary index b,c	266			
    Sociodemographic adjusted 1		0.88 (0.73-1.05)		0.16
    Lifestyle & disease adjusted 2		0.88 (0.72-1.07)		0.19





Table 2. Associations* between biological stress systems function at baseline and 
improvement of chronic multi-site musculoskeletal pain over 6 years follow-up (Continued)
		Improvement of chronic multi-site pain	





  Heart rate d	641			
    Sociodemographic adjusted 1		0.99 (0.90-1.09)		0.86
    Lifestyle & disease adjusted 2		1.00 (0.91-1.10)		0.96
    Depression & anxiety adjusted 3		0.99 (0.90-1.10)		0.88
  PEP d	632			
    Sociodemographic adjusted 1		1.03 (0.94-1.13)		0.56
    Lifestyle & disease adjusted 2		1.03 (0.94-1.13)		0.61
    Depression & anxiety adjusted 3		1.03 (0.93-1.14)		0.57
  SDNN d	641			
    Sociodemographic adjusted 1		1.03 (0.94-1.14)		0.48
    Lifestyle & disease adjusted 2		1.03 (0.94-1.13)		0.55
    Depression & anxiety adjusted 3		1.03 (0.94-1.14)		0.52
  RSAd,e	641			
    Sociodemographic adjusted 1		0.99 (0.89-1.11)		0.91
    Lifestyle & disease adjusted 2		0.98 (0.88-1.09)		0.66


























*Using Cox regression analyses; HR per 1 SD increase; ln-transformed variables were 
used for evening cortisol, post-dexamethasone cortisol and basal inflammatory markers. 
 1 adjusted for sex, age, years of education (and a cortisol sampling factors; c laboratory 
site; e respiration rate); 
2 additionally adjusted for alcohol intake, smoking, body mass index, number of chronic 
diseases and physical activity (and b use of anti-inflammatory medication; d use of 
β-blocking agents or other heart medication); 
3 additionally adjusted for lifetime diagnoses of depressive and anxiety disorders and 
use of antidepressants. 
ANS, autonomic nervous system; AUCg, area under the curve with respect to the ground; 
AUCi, area under the curve with respect to the increase; CRP, C-reactive protein; HPA-axis, 
hypothalamic-pituitary-adrenal axis; IL-6, interleukin-6;  IMS, immune system; LPS, 
lipopolysaccharide; PEP, pre-ejection period; RSA,  respiratory sinus arrhythmia; SDNN, 



























Table 3. Association* between adverse life events at baseline and 
improvement of chronic multi-site musculoskeletal pain over 6 years 
follow-up (n= 665)
	Improvement of chronic multi-site 
pain	
	HR (95%CI)	P
  Number of adverse life events		
    Sociodemographic adjusted 1	1.00 (0.93-1.09)	0.98
    Lifestyle & disease adjusted 2	1.02 (0.93-1.11)	0.71











* Using Cox regression analyses; HR per 1 additional life event.  
1 adjusted for sex, age, years of education; 
2 additionally adjusted for alcohol intake, smoking, body mass index, number 
of chronic diseases and physical activity;
3 additionally adjusted for lifetime diagnoses of depressive and anxiety 












Figure 1. Hypothetical framework suggesting that alterations in biological stress systems 
induce central sensitization, ultimately resulting in the persistence of chronic pain, an 
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